



Índice de intervenções por tema

B. IMAGING -> 03. IMAGING -> 03.1 ECHOCARDIOGRAPHY

- PO 2 A 3D-TTE LEFT ATRIAL FUNCTION STUDY IN CARDIO-ONCOLOGY PATIENTS
- PO 6 LEFT ATRIAL APPENDAGE VELOCITY AS AN INSTRUMENT OF PREDICTING ATRIAL FIBRILLATION RECURRENCE AFTER SUCCESSFUL CATHETER ABLATION - A USEFUL TOOL?
- PO 7 GLOBAL LONGITUDINAL STRAIN AS A PREDICTOR OF CARDIOVASCULAR EVENTS AND MORTALITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND HEART FAILURE WITH PRESERVED/MID-RANGE EJECTION FRACTION
- PO 10 IMPACT OF AN INCONCLUSIVE EXERCISE STRESS ECHOCARDIOGRAM ON CARDIOVASCULAR OUTCOMES
- PO 13 CAN WE USE LEFT ATRIAL EJECTION FRACTION (LAEF) TO IDENTIFY DIASTOLIC DYSFUNCTION?
- PO 15 DOES THE GENDER INFLUENCE IN MITRAL VALVE PROLAPSE CLINICAL PRESENTATION?
- PO 16 MITRAL ANNULUS DISJUNCTION: IS IT A MARKER OF OMINOUS PROGNOSIS?
- PO 30 REGURGITANT VOLUME TO LEFT VENTRICULAR END-DIASTOLIC VOLUME RATIO: THE QUEST TO IDENTIFY DISPROPORTIONATE MR IS NOT OVER
- PO 31 ASSESSING PROPORTIONATE AND DISPROPORTIONATE FUNCTIONAL MITRAL REGURGITATION WITH INDIVIDUALIZED THRESHOLDS OUTPERFORMS THE RISK STRATIFICATION PROPOSED BY CURRENT GUIDELINES
- PO 33 FUNCTIONAL MITRAL REGURGITATION PROFILE AND REFERRAL PATTERNS FOR MITRAL VALVE INTERVENTION OF A REAL-WORLD COHORT OF HEART FAILURE PATIENTS
- PO 103 FALSE POSITIVE RESULTS ON DOBUTAMINE STRESS ECHOCARDIOGRAPHY: A NEW MARKER OF RISK FOR ISCHEMIC EVENTS
- PO 105 ECHOCARDIOGRAPHIC DETERMINATION OF LVEF IN PATIENTS WITH A POOR ACOUSTIC WINDOW
- PO 112 LEFT VENTRICULAR NONCOMPACTION: THE IMPORTANCE OF IDENTIFYING HIGH-RISK PATIENTS WITHIN THE SCOPE OF LEFT VENTRICULAR HYPERTRABECULATION

B. IMAGING -> 03. IMAGING -> 03.2 COMPUTED TOMOGRAPHY

- PO 3 A META-ANALYSIS OF CORONARY CT ANGIOGRAPHY FOR PREDICTING LONG-TERM MAJOR ADVERSE CARDIAC EVENTS IN STABLE CORONARY ARTERY DISEASE
- PO 4 IMPLICATIONS OF CORONARY ARTERY CALCIUM IN PATIENTS WITH ATRIAL FIBRILLATION/FLUTTER UNDERGOING CATHETER ABLATION
- PO 12 CORONARY ARTERY CALCIUM SCORE TO PREDICT CORONARY CT ANGIOGRAPHY INTERPRETABILITY - AN OLD PROBLEM REVISITED
- PO 14 ANOMALOUS ORIGIN OF THE RIGHT CORONARY ARTERY WITH INTERARTERIAL COURSE: RED FLAG OR INNOCENT BYSTANDER?
- PO 17 EPICARDIAL FAT VOLUME IMPROVES PREDICTION OF ADVERSE CLINICAL EVENTS

B. IMAGING -> 03. IMAGING -> 03.3 CARDIAC MAGNETIC RESONANCE

- PO 1 CHARACTERIZATION OF MYOCARDIAL DEFORMATION IN ALL FOUR CARDIAC CHAMBERS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY USING FEATURE TRACKING CARDIAC MAGNETIC RESONANCE IMAGING
- PO 5 THE ROLE OF CARDIAC MAGNETIC RESONANCE TO STUDY UNEXPLAINED OR SUSPECTED ARRHYTHMIAS
- PO 9 THE ODYSSEY TO DETHRONE LV EJECTION FRACTION CONTINUES: THE PROGNOSTIC VALUE OF LV GLOBAL FUNCTION INDEX IN HEART FAILURE
- PO 11 PREDICTORS OF THE PRESENCE OF SEPTAL LATE GADOLINIUM ENHANCEMENT IN FOLLOW-UP CARDIAC MAGNETIC RESONANCE IMAGING AND ITS RELATION TO ACUTE MYOCARDITIS PROGNOSIS
- PO 102 TEMPORAL CHARACTERIZATION OF VENTRICULAR FUNCTION AND DEFORMATION AFTER TAKOTSUBO SYNDROME USING CARDIOVASCULAR MAGNETIC RESONANCE IMAGING
- PO 104 THE ROLE OF CARDIAC MAGNETIC RESONANCE IN MINOCA DIAGNOSIS
- PO 144 LOOKING BEYOND LEFT VENTRICULAR EJECTION FRACTION - A NEW MULTIPARAMETRIC CMR SCORE TO REFINE THE PROGNOSTIC ASSESSMENT OF HF PATIENTS

B. IMAGING -> 03. IMAGING -> 03.4 NUCLEAR IMAGING

- PO 146 CORONARY COLLATERALS GRADING IN CHRONIC TOTAL OCCLUSIONS: IS IT ENOUGH TO PRESUME ISCHEMIA AND VIABILITY?

B. IMAGING -> 03. IMAGING -> 03.6 CROSS-MODALITY AND MULTI-MODALITY IMAGING TOPICS

- PO 8 PATIENTS UNDERGOING INVASIVE CORONARY ANGIOGRAPHY AFTER A POSITIVE SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY OR A POSITIVE STRESS CARDIAC MAGNETIC RESONANCE - WHAT TO EXPECT AT THE CATH LAB

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.1 ARRHYTHMIAS, GENERAL - PATHOPHYSIOLOGY AND MECHANISMS

- PO 80 ASSESSMENT OF WAVEFRONT PROPAGATION SPEED ON THE RIGHT VENTRICULAR OUTFLOW TRACT: DECELERATION ZONES ASSOCIATED WITH THE PRESENCE OF LOW VOLTAGE AREAS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.3 ARRHYTHMIAS, GENERAL - DIAGNOSTIC METHODS

- PO 52 THREE-DIMENSIONAL LATE GADOLINIUM ENHANCEMENT INCREASES THE DIAGNOSTIC YIELD OF CARDIOVASCULAR MAGNETIC RESONANCE TO DETECT LOW VOLTAGE IN THE RIGHT VENTRICULAR OUTFLOW TRACT
- PO 71 OPEN-WINDOW AND AUTOMATED ACCESSORY PATHWAY MAPPING IN WOLFF-PARKINSON-WHITE SYNDROME

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.4 ARRHYTHMIAS, GENERAL - TREATMENT

- PO 53 LOW-FLUORO WORKFLOWS AND IMPACT IN RADIATION EXPOSURE IN THE ELECTROPHYSIOLOGY LABORATORY
- PO 16 CATHETER ABLATION OF LONG-STANDING PERSISTENT ATRIAL FIBRILLATION: THE UGLY TYPE OF AF?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.2 ATRIAL FIBRILLATION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 55 LEFT ATRIAL STRAIN IMAGING EVALUATION: A STRONG PREDICTOR OF ATRIAL FIBRILLATION RECURRENCE AFTER SINGLE-PROCEDURE CATHETER ABLATION
- PO 56 BASELINE LEFT ATRIAL STRAIN IMAGING ASSESSMENT PREDICTS ARRHYTHMIA RECURRENCE IN PATIENTS WITH PAROXYSMAL OR PERSISTENT ATRIAL FIBRILLATION UNDERGOING CATHETER ABLATION
- PO 70 SINGLE-SHOT COMPARED TO POINT-BY-POINT ATRIAL FIBRILLATION ABLATION SUCCESS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.3 ATRIAL FIBRILLATION - DIAGNOSTIC METHODS

PO 72 ELECTROCARDIOGRAPHIC MARKERS OF INCIDENT ATRIAL FIBRILLATION IN PATIENTS WITH CRYPTOGENIC STROKE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.4 ATRIAL FIBRILLATION - TREATMENT

PO 54 A QUESTION OF TIME: ABLATION INDEX MAY SPARE THE WAITING PERIOD AFTER PULMONARY VEIN ISOLATION

PO 58 MYOCARDIAL INJURY AFTER PULMONARY VEIN ISOLATION: FIRE VERSUS ICE

PO 63 CHRONIC DIGOXIN UTILIZATION IN PATIENTS WITH ATRIAL FIBRILLATION IS ASSOCIATED WITH HOSPITALIZATION FOR DE NOVO ACUTE HEART FAILURE

PO 64 REDO ABLATION FOR ATRIAL FIBRILLATION RECURRENCE POST RADIOFREQUENCY OR CRYOBALLOON ABLATION: A HIGH VOLUME SINGLE-CENTRE EXPERIENCE

PO 69 CATHETER ABLATION AS A TREATMENT FOR ATRIAL FIBRILLATION: EXPERIENCE AND RESULTS FROM A HIGH VOLUME PORTUGUESE TERTIARY CENTER

PO 73 ELECTRICAL ANATOMY OF THE LEFT ATRIUM DURING ATRIAL FIBRILLATION

PO 74 CLOSE PROTOCOL WITH CENTER-SPECIFIC ABLATION INDEX TARGET IN AF ABLATION

PO 79 PORTUGUESE INITIAL EXPERIENCE OF ATRIAL FIBRILLATION ABLATION USING LASER BALLOON

PO 80 PVI ONLY VERSUS PVI WITH COMPLEMENTING STRATEGIES - LESS IS MORE

PO 83 EARLY DISCHARGE AFTER CRYOABLATION PROCEDURE: IS IT SAFE?

PO 85 NO NEED FOR COLD FEET - EFFICACY OF CRYOABLATION VERSUS OTHER ABLATION TECHNIQUES

PO 87 ATRIAL FIBRILLATION ABLATION USING HIGH-DENSITY VOLTAGE MAPPING WITH A SIMPLIFIED SINGLE TRANSEPTAL PUNCTURE APPROACH: LONG-TERM OUTCOME OF A SINGLE-CENTER EXPERIENCE

PO 12 PREVALENCE AND PREDICTOR FACTORS OF PERSISTENT PULMONARY VEIN ISOLATION IN REDO AF ABLATION PROCEDURE

PO 14 RADIOFREQUENCY CATHETER ABLATION FOR PERSISTENT ATRIAL FIBRILLATION

PO 69 IMPACT OF PULMONARY VEINS ANATOMY ON OUTCOME OF CRYOABLATION OR RADIOFREQUENCY CATHETER ABLATION FOR ATRIAL FIBRILLATION

PO 71 CRYOBALLOON VERSUS RADIOFREQUENCY GUIDED BY ABLATION INDEX FOR ATRIAL FIBRILLATION ABLATION: A RETROSPECTIVE PROPENSITY-MATCHED STUDY

PO 73 IS BALLOON CRYOABLATION EFFECTIVE IN COMMON PULMONARY TRUNK?

PO 145 NOT A COLD SUCCESS - EFFICACY OF CRYOABLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.5 ATRIAL FIBRILLATION - STROKE PREVENTION

PO 67 LONG-TERM OUTCOMES OF VITAMIN K ANTAGONISTS VERSUS DIRECT ORAL ANTICOAGULATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.7 ATRIAL FIBRILLATION - PREVENTION

PO 17 LONG-TERM RISK OF MAJOR CARDIOVASCULAR EVENTS AFTER CAVOTRICUSPID ISTHMUS ABLATION: WHEN AND IN WHOM TO DISCONTINUE ORAL ANTICOAGULATION?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.8 ATRIAL FIBRILLATION - CLINICAL

PO 48 PERICARDIAL FLUID AND SERUM NT-PRO-BNP AND GDF-15 IN PATIENTS WITH ATRIAL FIBRILLATION SUBMITTED TO AORTIC VALVE REPLACEMENT SURGERY

PO 68 ARRHYTHMIA-INDUCED CARDIOMYOPATHY: UNVEILED AFTER ELECTRICAL CARDIOVERSION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.9 ATRIAL FIBRILLATION - OTHER

- PO 61 REAL-WORLD COMPARISON OF DIFFERENT PERIPROCEDURAL ANTITHROMBOTIC STRATEGIES FOR ATRIAL FIBRILLATION CATHETER ABLATION
- PO 89 ALCOHOL CONSUMPTION AND ATRIAL FIBRILLATION/FLUTTER - WHAT IS THE IMPACT?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.2 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 75 TYPICAL ATRIAL FLUTTER ABLATION - PREDICTORS OF EVENTS IN THE FOLLOW-UP
- PO 76 IS CHA2DS2VASC SCORE RELIABLE AS PROGNOSTIC MARKER IN ATRIAL FLUTTER?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.4 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - TREATMENT

- PO 59 RADIOFREQUENCY CATHETER ABLATION OF FOCAL ATRIAL TACHYCARDIA: CHARACTERISTICS AND RESULTS OF A SERIE IN A TERTIARY HOSPITAL
- PO 60 SHORT-TERM ATRIAL TACHYCARDIA RECURRENCE AND CLINICAL IMPROVEMENT AFTER CATHETER ABLATION: ARE THERE WORST RESULTS IN STRUCTURAL HEART DISEASE?
- PO 72 WITHDRAWAL OF ANTI-ARRHYTHMIC THERAPY AFTER CAVO-TRICUSPID ISTHMUS ABLATION OF TYPICAL ATRIAL FLUTTER
- PO 13 A NEW APPROACH TO ATRIAL FLUTTER ABLATION USING FUNCTIONAL SUBSTRATE MAPPING WITH WAVEFRONT DISCONTINUITY DURING SINUS RHYTHM
- PO 15 A NEW ELECTROPHYSIOLOGICAL TRIAD FOR ATRIAL FLUTTER CRITICAL ISTHMUS IDENTIFICATION AND LOCALIZATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.6 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - CLINICAL

- PO 70 PREDICTORS OF ARRHYTHMIC RECURRENCE AFTER TYPICAL ATRIAL FLUTTER ABLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.3 SYNCOPE AND BRADYCARDIA - DIAGNOSTIC METHODS

- PO 59 FRONT-LOADED HEAD-UP TILT TABLE TESTING FOR THE DIAGNOSIS OF REFLEX SYNCOPE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.4 SYNCOPE AND BRADYCARDIA - TREATMENT

- PO 57 SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR DEBILITATING VASOVAGAL SYNCOPE: LOOKING FOR COPPER AND FINDING GOLD
- PO 60 LONG-TERM OUTCOMES IN PATIENTS WITH POTENTIAL REVERSIBLE CAUSES OF BRADYCARDIA

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.5 SYNCOPE AND BRADYCARDIA - PREVENTION

- PO 58 QUALITY OF LIFE IN REFLEX SYNCOPE PATIENTS: BENEFITS OF A SYSTEMATIC EDUCATIONAL PREVENTION PROGRAM.
- PO 62 PREDICTING REFLEX SYNCOPE BASED ON PLETHYSMOGRAPHY: A NEW WEARABLE DEVICE DEVELOPMENT AND PRELIMINARY RESULTS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.2 VENTRICULAR ARRHYTHMIAS AND SCD - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 82 PROGNOSTIC ROLE OF NON-SUSTAINED VENTRICULAR TACHYCARDIA IN NONISCHEMIC CARDIOMYOPATHY
- PO 79 LONG TERM PROGNOSIS OF OUT-OF-HOSPITAL CARDIAC ARREST DUE TO IDIOPATHIC VENTRICULAR FIBRILLATION -A TERTIARY CENTER EXPERIENCE
- PO 82 LONG QT SYNDROME - EXPERIENCE FROM A PORTUGUESE CENTER

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.4 VENTRICULAR ARRHYTHMIAS AND SCD - TREATMENT

- PO 49 SAFETY AND EFFICACY OF IDIOPATHIC OUTFLOW TRACT VENTRICULAR ARRHYTHMIAS ABLATION
- PO 81 CATHETER ABLATION SUPPORTED BY EXTRACORPOREAL MEMBRANE OXYGENATION - LAST RESORT TREATMENT OF ARRHYTHMIC STORM?
- PO 83 LONG-TERM OUTCOME OF VENTRICULAR TACHYCARDIA CATHETER ABLATION IN ISCHEMIC HEART DISEASE PATIENTS USING A HIGH-DENSITY MAPPING SUBSTRATE-BASED APPROACH: A PROSPECTIVE COHORT STUDY.
- PO 84 VENTRICULAR TACHYCARDIA ABLATION IN NONISCHEMIC CARDIOMYOPATHY

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.1 ANTIBRADYCARDIA PACING

- PO 50 RIGHT VENTRICULAR SEPTAL VERSUS APICAL PACING: LONG-TERM INCIDENCE OF HEART FAILURE AND SURVIVAL
- PO 62 THE ROLE OF THE CHARLSON COMORBIDITY INDEX IN PREDICTING LONG-TERM SURVIVAL AFTER PERMANENT PACEMAKER IMPLANTATION - IS OLD AGE ALL THAT MATTERS?
- PO 61 ATRIOVENTRICULAR SYNCHRONOUS PACING USING A LEADLESS VENTRICULAR PACEMAKER: SINGLE CENTRE EXPERIENCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.2 IMPLANTABLE CARDIOVERTER / DEFIBRILLATOR

- PO 57 SEPTAL VERSUS APICAL CARDIOVERTER-DEFIBRILLATOR RIGHT VENTRICLE ELECTRODE PLACEMENT - A SYSTEMATIC REVIEW ON LONG-TERM FOLLOW-UP
- PO 119 WHAT IS THE MORTALITY IMPACT OF SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR INAPPROPRIATE SHOCKS?
- PO 123 HOW TO PREDICT MORTALITY IN PATIENTS UNDERGOING ICD IMPLANTATION - IS CREATININE THE NEW AGE?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.3 CARDIAC RESYNCHRONIZATION THERAPY

- PO 51 OPTIMAL PERCENTAGE OF BIVENTRICULAR PACING TO OBTAIN CRT-RESPONSE: HOW HIGH IS HIGH ENOUGH
- PO 66 ECHOCARDIOGRAPHIC BUT NOT CLINICAL RESPONSE TO CRT IS AN INDEPENDENT PREDICTOR OF A BETTER SURVIVAL FREE FROM ARRHYTHMIC EVENTS
- PO 77 THE IMPACT OF GLOMERULAR FILTRATION RATE IN PATIENTS WITH HEART FAILURE AND CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICES
- PO 78 RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY: WHAT ABOUT THE NON-RESPONDERS?
- PO 81 RE-EVALUATION OF RESPONSE TO CRT: LONG-TERM IMPACT OF ECHOCARDIOGRAPHIC NON-PROGRESSION
- PO 84 QRS NARROWING PREDICTS LEFT VENTRICULAR REVERSE REMODELLING AFTER RESYNCHRONIZATION THERAPY IN PATIENTS WITH END-STAGE HEART FAILURE
- PO 86 IMPACT OF ATRIAL FIBRILLATION AND BIVENTRICULAR PACING PERCENTAGE ON LONG-TERM OUTCOME IN PATIENTS WITH HEART FAILURE TREATED WITH CARDIAC RESYNCHRONIZATION THERAPY

- PO 88 THE RESULTS OF A CARDIAC RESYNCHRONIZATION PROGRAM IN A DISTRICT HOSPITAL
- PO 121 HEART FAILURE HOSPITALIZATION AND SURVIVAL AFTER CARDIAC RESYNCHRONIZATION THERAPY IN ELDERLY POPULATION
- PO 122 COULD QRS DURATION ADJUSTED TO BMI AND BSA PREDICT CARDIAC RESYNCHRONIZATION THERAPY RESPONSE?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.6 DEVICE THERAPY - OTHER

- PO 65 PROGNOSTIC SIGNIFICANCE OF NON-SUSTAINED VENTRICULAR TACHYCARDIA ON STORED ELECTROGRAMS OF HEART FAILURE PATIENTS WITH CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICES

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.2 CHRONIC HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 18 REAL-WORLD IMPACT OF SACUBITRIL/VALSARTAN ON THE QUALITY OF LIFE OF HEART FAILURE PATIENTS
- PO 26 CARDIOPULMONARY EXERCISE TESTING IN HEART FAILURE: THE ROLE OF CLASSIC AND NEW VARIABLES IN EVENT PREDICTION
- PO 30 ECHOCARDIOGRAPHIC PREDICTORS OF EXERCISE INTOLERANCE IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 44 HEART FAILURE HOSPITALIZATIONS DURING COVID19 OUTBREAK: IS THE SYSTEM FAILING THE HEART?
- PO 42 RECALIBRATING THE MECKI SCORE IN A PORTUGUESE COHORT OF PATIENTS WITH HEART FAILURE
- PO 54 DO ALPHA-ADRENERGIC BLOCKERS REALLY INCREASE THE RISK OF POOR CARDIOVASCULAR OUTCOMES? AN ACROSS-THE-BOARD META-ANALYSIS
- PO 56 RESSINCRONIZAÇÃO CARDÍACA EM DOENTES COM INSUFICIÊNCIA CARDÍACA GRAVE: É POSSIVEL PREVER O PROGNÓSTICO AOS 5 ANOS?
- PO 63 PREDICTIVE ABILITY OF CARDIOPULMONARY EXERCISE TEST PARAMETERS IN HEART FAILURE PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY
- PO 67 EXERCISE OSCILLATORY VENTILATION DISTURBANCES: FINDING ORDER AMONGST CHAOS
- PO 124 PREDICTORS OF VENTRICULAR ARRHYTHMIAS AND MORTALITY AFTER IMPLANTATION OF PRIMARY PREVENTION ANTITACHYCARDIA DEVICES

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.3 CHRONIC HEART FAILURE - DIAGNOSTIC METHODS

- PO 29 IMPACT OF LOCKDOWN MEASURES DURING COVID-19 PANDEMIC IN ACTIVITY LEVEL OF PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY DEVICE: REMOTE MONITORING DATA FROM THE TRIAGE-HF RISK SCORE
- PO 41 SARCOPENIA IN HEART FAILURE: WHEN THE IMAGE HOLDS MORE THAN THE BLOOD
- PO 52 PREDICTING OBSTRUCTIVE CORONARY ARTERY DISEASE IN HEART FAILURE - A PRACTICAL CLINICAL SCORE

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.4 CHRONIC HEART FAILURE - TREATMENT

- PO 21 ASSESSING LEFT ATRIAL AND LEFT VENTRICULAR STRAIN IMAGING: IS THERE AN IMPROVEMENT OF ATRIAL AND VENTRICULAR FUNCTION WITH SACUBITRIL/VALSARTAN?
- PO 22 SACUBITRIL/VALSARTAN REAL-WORLD PERSISTENCE USING A COHORT OF HEART FAILURE PATIENTS FROM THE PRESCRIPTION & MONITORING OF SACUBITRIL/VALSARTAN STUDY (PRIME 2 STUDY)
- PO 23 SUPERRESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY: CLINICAL OUTCOMES AND PREDICTORS
- PO 25 REAL WORLD NONINVASIVE EVALUATION OF THE ACUTE HEMODYNAMIC EFFECTS OF LEVOSIMENDAN CONTINUOUS INFUSION IN ADVANCED HEART FAILURE PATIENTS
- PO 33 MYOCARDIAL ACTIVATION VELOCITY IN THE SELECTION OF CRT CANDIDATES

- PO 34 OPTIMIZED MEDICAL THERAPY IN NON-ISCHEMIC HEART FAILURE - HOW ABOUT REAL LIFE?
- PO 36 VALIDATION OF A NOVEL FRAMEWORK DEFINING THE ACCEPTABLE STANDARD OF CARE FOR HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 37 PROGNOSIS SIGNIFICANCE OF REACHING OPTIMAL MEDICAL THERAPY IN PATIENTS WITH HEART FAILURE- A REAL LIFE OVERVIEW
- PO 38 WE NEED TO TREAT OUR WOMEN BETTER
- PO 42 EFFECTIVENESS AND SAFETY OF SACUBITRIL/VALSARTAN IN PATIENTS WITH STAGE 4 CHRONIC KIDNEY DISEASE IN A REAL-WORLD POPULATION
- PO 45 DIURETIC DOSE IN CHRONIC HEART FAILURE - THE LOWER THE BETTER?
- PO 46 USE OF RENIN-ANGIOTENSIN-ALDOSTERON INHIBITORS (RASSI) AND DOSE-RELATED OUTCOMES IN OLDER ADULTS
- PO 47 SEQUENTIAL NEPHRON BLOCKADE: A BLOCKER IN HEART FAILURE?
- PO 40 PROGNOSTIC IMPACT OF DIGOXIN USE IN A HEART FAILURE POPULATION
- PO 43 RIGHT VENTRICULAR DYSFUNCTION IS A PREDICTOR OF NON-RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY
- PO 44 SACUBITRIL/VALSARTAN IN HFREF PATIENTS WITH LOW NT-PROBNP LEVELS - ANY BENEFIT?
- PO 53 C-REACTIVE PROTEIN REDUCTION WITH SACUBITRIL-VALSARTAN TREATMENT IN HEART FAILURE PATIENTS
- PO 55 PREDICTORS OF MAXIMAL DOSE TITRATION OF SACUBITRIL-VALSARTAN
- PO 120 OUTCOMES AND PREDICTORS OF CLINICAL RESPONSE AFTER UPGRADE TO RESYNCHRONIZATION THERAPY
- PO 141 METFORMIN IMPROVES DIASTOLIC DYSFUNCTION OF NON-DIABETIC PATIENTS WITH METABOLIC SYNDROME: THE MET-DIME RANDOMIZED TRIAL

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.6 CHRONIC HEART FAILURE - CLINICAL

- PO 27 THE RIGHT VENTRICLE: PAIRING STRUCTURAL WITH FUNCTIONAL ASSESSMENT
- PO 32 CARDIOPULMONARY TESTING IN PATIENTS WITH HEARTMATE 3 LEFT VENTRICULAR ASSIST DEVICE

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.7 CHRONIC HEART FAILURE - OTHER

- PO 28 THE REPRESENTATIVENESS OF VICTORIA AND GALACTIC-HF TRIALS IN A CONTEMPORARY COHORT OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 51 PILL BURDEN AND OUT-OF-POCKET MEDICATION COSTS OF A CONTEMPORARY HEART FAILURE WITH REDUCED EJECTION FRACTION COHORT

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.1 ACUTE HEART FAILURE - PATHOPHYSIOLOGY AND MECHANISMS

- PO 118 ENDOCAN - A POTENTIAL NEW BIOMARKER OF INFLAMMATION-DRIVEN "ENDOTHELITIS" IN HUMAN ACUTE HEART FAILURE AND CARDIOGENIC SHOCK

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.2 ACUTE HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 20 BNP PERCENTAGE DECREASE DURING HOSPITALIZATION AND ITS PROGNOSIS IN HEART FAILURE
- PO 24 AHFM SCORE, A PREDICTIVE MODEL OF IN-HOSPITAL AND LONG-TERM MORTALITY IN HEART FAILURE
- PO 31 READMISSIONS IN HEART FAILURE PATIENTS: A PORTUGUESE ADMINISTRATIVE DATABASE STUDY FROM 2008 TO 2018
- PO 35 PROGNOSTIC VALUE OF RELATIVE WALL THICKNESS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: WHAT IS THE BEST METHOD FOR ITS CALCULATION?
- PO 39 PREDICTING EARLY IN-HOSPITAL OUTCOMES IN ACUTE HEART FAILURE
- PO 40 GRACE SCORE VERSUS GWTG-HF SCORE: RISK STRATIFICATION IN ACUTE HEART FAILURE
- PO 41 PAMI SCORE IN ACUTE HEART FAILURE PATIENTS: AN ADDITIONAL VALUE?

- PO 113 PATIENTS ADMITTED WITH ACUTE HEART FAILURE AT AN INTENSIVE CARE DEPARTMENT OF A TERTIARY CARE HOSPITAL - CHARACTERIZATION OF PATIENTS SUBMITTED TO MECHANICAL CIRCULATORY SUPPORT
- PO 114 DIURETIC RESPONSE IN ACUTE HEART FAILURE PATIENTS PREDICTS 30-DAY HOSPITALIZATION OR EMERGENCY DEPARTMENT VISIT
- PO 115 ACUTE HEART FAILURE: DOES MIDRANGE EJECTION FRACTION RESULT IN MIDRANGE PROGNOSIS?
- PO 116 BAUN SCORE, A BETTER PREDICTIVE MODEL OF IN-HOSPITAL AND LONG-TERM OUTCOMES IN ACUTE HEART FAILURE?
- PO 117 THE C-REACTIVE PROTEIN/ALBUMIN RATIO AS A PREDICTOR OF MORTALITY IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION.

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.4 ACUTE HEART FAILURE- TREATMENT

- PO 19 CLINICAL PREDICTORS OF IN-HOSPITAL MORTALITY IN PATIENTS ADMITTED WITH ACUTE HEART FAILURE IN AN INTENSIVE CARE DEPARTMENT
- PO 43 CAN WE PREDICT MORTALITY AND READMISSION RATE IN ACUTE HEART FAILURE TREATED WITH LEVOSIMENDAN?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.1 CORONARY ARTERY DISEASE - PATHOPHYSIOLOGY AND MECHANISMS

- PO 113 CORRELATION OF BODY MASS INDEX, HIGH-SENSITIVITY C-REACTIVE PROTEIN AND PROGNOSIS IN A PORTUGUESE POPULATION WITH CORONARY ARTERY DISEASE

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.2 CORONARY ARTERY DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 128 GENOMIC PREDICTION OF CARDIOVASCULAR EVENTS IN A CORONARY SOUTHERN EUROPEAN POPULATION
- PO 133 ANOMALOUS ORIGIN OF THE CORONARIES ARTERIES - EXPERIENCE OF A LARGE VOLUME CENTER ENCOMPASSING OVER 25 YEARS
- PO 19 A GENETIC RISK SCORE PREDICTS RECURRENT EVENTS AFTER MYOCARDIAL INFARCTION IN YOUNG PATIENTS WITH A LOW LEVEL OF TRADITIONAL RISK FACTORS
- PO 22 HNF4A GENE CAN BE A GENETIC PROTECTOR FOR CORONARY ARTERY DISEASE
- PO 143 CAN GENE-GENE INTERACTION BETTER PREDICT THE CORONARY DISEASE RISK?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.3 CORONARY ARTERY DISEASE - DIAGNOSTIC METHODS

- PO 119 PREDICTORS OF OBSTRUCTIVE CORONARY ARTERY DISEASE IN ELECTIVE CORONARY ANGIOGRAPHY
- PO 130 DIAGNOSIS OF CHRONIC OBSTRUCTIVE CORONARY ARTERY DISEASE: IS NON-INVASIVE TESTING THE SUITABLE GATEKEEPER FOR CORONARY ANGIOGRAPHY?
- PO 132 QUANTIFICATION OF EPICARDIAL FAT WITH CARDIAC CT AND ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS AND OBSTRUCTIVE CORONARY DISEASE
- PO 134 EXERCISE ECHOCARDIOGRAPHY IN PATIENTS WITH SUSPECTED OR KNOWN CORONARY ARTERY DISEASE - IS THERE STILL A ROLE FOR ELECTROCARDIOGRAPHIC CHANGES?
- PO 142 DOBUTAMINE STRESS ECHOCARDIOGRAPHY FOR ASSESSMENT OF MYOCARDIAL VIABILITY: ACCURACY AND IMPACT OF BETA-BLOCKADE ON THE RESULTS
- PO 1 AGE AND FUNCTIONAL RELEVANCE OF CORONARY STENOSIS: A POST-HOC ANALYSIS OF THE ADVISE II TRIAL
- PO 3 PRE-TEST PROBABILITY OF CHRONIC CORONARY SYNDROME

- PO 4 ISCHEMIA LBBB STUDY - IS AN ANATOMICAL APPROACH SUPERIOR TO A FUNCTIONAL APPROACH FOR THE DIAGNOSIS OF OBSTRUCTIVE CORONARY ARTERY DISEASE IN PATIENTS WITH LEFT BUNDLE BRANCH BLOCK?
- PO 5 INCORPORATING CORONARY CALCIFICATION INTO PRETEST ASSESSMENT OF THE LIKELIHOOD OF CORONARY ARTERY DISEASE - VALIDATION AND RECALIBRATION OF A NEW DIAGNOSTIC TOOL
- PO 18 VIRTUAL FRACTIONAL FLOW RESERVE DERIVED FROM CORONARY ANGIOGRAPHY -ARTERY AND LESION SPECIFIC CORRELATIONS
- PO 74 PHYSIOLOGICAL CHANGES ASSOCIATED TO AGEING IN THE CORONARY CIRCULATION AND ITS RELEVANCE FOR HYPERAEMIC AND NON-HYPERAEMIC INDICES OF STENOSIS RELEVANCE
- PO 77 FEASIBILITY OF VIRTUAL FRACTIONAL FLOW RESERVE DERIVED FROM CORONARY ANGIOGRAPHY AND ITS CORRELATION WITH INVASIVE FUNCTIONAL ASSESSMENT

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.6 CORONARY ARTERY DISEASE - CLINICAL

- PO 148 SELEÇÃO DE DOENTES PARA CORONARIOGRAFIA INVASIVA ELECTIVA - ESTAMOS A FAZER BEM?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.1 ACUTE CORONARY SYNDROMES - PATHOPHYSIOLOGY AND MECHANISMS

- PO 144 THE PERCEIVED STRESS IN ACUTE CORONARY SYNDROME PATIENTS

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.2 ACUTE CORONARY SYNDROMES - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 90 EFFECT OF SEVERE ANEMIA (HEMOGLOBIN < 10G/DL) ON SHORT- AND LONG-TERM OUTCOME IN ACUTE CORONARY SYNDROME: INSIGHTS OF A TERTIARY CENTRE
- PO 91 WHAT IS THE PROGNOSIS FOR PATIENTS WHO DEVELOP NEW-ONSET ATRIAL FIBRILLATION IN THE FIRST 48 HOURS AFTER AN ACUTE CORONARY SYNDROME?
- PO 95 YOUNG PATIENTS WITH ACS: WHO ARE THEY AND WHERE ARE THEY GOING?
- PO 99 WHAT ARE THE PREDICTORS OF HEART FAILURE IN PATIENTS ADMITTED WITH ACUTE CORONARY SYNDROME? - DATA FROM A LARGE NATIONAL REGISTRY
- PO 100 DE NOVO ATRIAL FIBRILLATION IN ACUTE CORONARY SYNDROMES: IS CHAD2S2VASC USEFUL?
- PO 101 EARLY AND LATE ONSET SUSTAINED VENTRICULAR TACHYCARDIA IN ACUTE CORONARY SYNDROME
- PO 102 IMPACT OF COVID-19 PANDEMIC ON ST-ELEVATION MYOCARDIAL INFARCTION: DATA FROM TWO PORTUGUESE CENTERS
- PO 103 ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION - ARE WOMEN BEING DISCRIMINATED?
- PO 104 WONDER WOMAN AFTER AN ACUTE CORONARY SYNDROME
- PO 106 IMPACT OF PREHOSPITAL ELECTROCARDIOGRAM ON TIME TO TREATMENT AND IN-HOSPITAL OUTCOMES IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
- PO 107 ACUTE CORONARY SYNDROME: APPLICATION OF THE GRACE SCORE, TIMI SCORE AND CREATION OF A NEW LABORATORIAL SCORE
- PO 111 IS MAJOR BLEEDING RELATED TO THE TIMING OF INTERVENTION IN NSTEMI-ACS?
- PO 112 PRECISE-DAPT SCORE FOR LONG-TERM BLEEDING PREDICTION AFTER ACUTE CORONARY SYNDROME IN PATIENTS MANAGED WITHOUT PERCUTANEOUS CORONARY INTERVENTION
- PO 114 ACUTE CORONARY SYNDROME IN A PANDEMIC: WHAT ABOUT NSTEMI?
- PO 115 MYOCARDIAL INFARCTION, DIABETES AND HEART FAILURE: A DEADLY COMBINATION
- PO 118 IMPACT OF ATRIAL FIBRILLATION TYPE IN ACUTE CORONARY SYNDROME AND ANTITHROMBOTIC STRATEGY
- PO 121 ATRIOVENTRICULAR BLOCK IN ACUTE CORONARY SYNDROME PATIENTS
- PO 123 ANTITHROMBOTIC STRATEGY IN PATIENTS WITH ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROME

- PO 126 ACUTE CORONARY SYNDROMES IN THE ELDERLY: PROGNOSTIC IMPACT OF ANAEMIA
- PO 127 STEMI AROUND-THE-CLOCK: HOW OFF-HOURS ADMISSIONS IMPACT DOOR-TO-BALLOON TIME AND THE LONG-TERM PROGNOSIS OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION.
- PO 136 PREDICTORS OF MECHANICAL COMPLICATIONS AFTER ACUTE MYOCARDIAL INFARCTION- A LARGE RETROSPECTIVE STUDY
- PO 137 THE IMPACT OF HAEMOGLOBIN VARIATION IN PATIENTS WITH ACUTE CORONARY SYNDROME
- PO 138 PROGNOSTIC IMPACT OF WORSENING RENAL FUNCTION PARAMETERS IN PATIENTS WITH ACUTE CORONARY SYNDROME
- PO 139 WHAT IS THE PROGNOSTIC IMPACT OF INFLAMMATION IN ACUTE CORONARY SYNDROME?
- PO 140 PROGNOSTIC IMPACT OF ACUTE KIDNEY INJURY IN MAJOR BLEEDING IN ACUTE CORONARY SYNDROME PATIENTS
- PO 141 CAN PULMONARY ARTERY SYSTOLIC PRESSURE PREDICT OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES?
- PO 143 SERUM ALBUMIN: PROGNOSTIC VALUE IN PATIENTS WITH ACUTE CORONARY SYNDROME
- PO 147 SHOULD HIV BE ROUTINELY SCREENED DURING ACS ADMISSION? RESULTS FROM A COHORT OF OVER 3,000 CONSECUTIVE PATIENTS
- PO 20 CIRCULATING ENDOTHELIAL PROGENITOR CELLS AS PREDICTORS OF LONG-TERM CARDIOVASCULAR MORTALITY AFTER MYOCARDIAL INFARCTION: WHICH DEFINITION SHOULD WE USE?
- PO 21 THE QUEST FOR GRACE 3.0: IMPROVING OUR BELOVED RISK SCORE WITH MACHINE LEARNING

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.3 ACUTE CORONARY SYNDROMES - DIAGNOSTIC METHODS

- PO 96 PREDICTIVE VALUE OF CEREBRAL NATRIURETIC PEPTIDE IN ACUTE MYOCARDIAL INFARCTION WITHOUT OBSTRUCTIVE CORONARY DISEASE
- PO 2 RAPID ATRIAL FIBRILLATION INCREASES CARDIAC BIOMARKERS: DECISION TO PERFORM CORONARY ANGIOGRAPHY BASED ON NOVEL HIGH-SENSITIVITY TROPONIN I PEAK

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.4 ACUTE CORONARY SYNDROMES - TREATMENT

- PO 93 COMPLETE REVASCULARIZATION IN STEMI WITH MULTIVESSEL DISEASE: HOW LATE IS TOO LATE?
- PO 94 GLYCOPROTEIN IIB-IIIA RECEPTOR INHIBITORS IN ACUTE CORONARY SYNDROME PATIENTS PRESENTING WITH CARDIOGENIC SHOCK: A NATION-WIDE REGISTRY
- PO 97 OUTCOME FOLLOWING LATE REPERFUSION WITH PERCUTANEOUS CORONARY INTERVENTION IN STABLE PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PRESENTING MORE THAN 12 HOURS FROM ONSET OF SYMPTOMS IN THE CONTEMPORARY ERA
- PO 109 CHARACTERIZATION AND QUALITY OF CARE INDICATORS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITHOUT ST SEGMENT ELEVATION
- PO 110 OPTIMAL TIMING OF INTERVENTION IN NSTEMI-ACS WITHOUT PRE-TREATMENT
- PO 116 INDIRECT EFFECTS OF COVID-19 PANDEMIC IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM A MULTICENTRIC NATIONAL SURVEY
- PO 120 MULTIVESSEL DISEASE IN ST- ELEVATION MYOCARDIAL INFARCTION: WHAT IS THE BEST TIMING FOR COMPLETE REVASCULARIZATION?
- PO 125 FAILURE OF PERCUTANEOUS CORONARY INTERVENTION AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: WHAT HAPPENS IN 5 YEARS?
- PO 129 PERFORMANCE OF BLEEDING RISK SCORES IN PATIENTS WITH ACUTE CORONARY SYNDROME
- PO 131 ON- VERSUS OFF-HOURS PRIMARY PERCUTANEOUS CORONARY INTERVENTION: A SINGLE-CENTRE EXPERIENCE
- PO 75 STENT-SAVE A LIFE INTERNATIONAL SURVEY ON THE PRACTICE OF PRIMARY CORONARY ANGIOPLASTY DURING THE COVID-19 PANDEMIC.

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.6 ACUTE CORONARY SYNDROMES - CLINICAL**

- PO 98 SPONTANEOUS CORONARY ARTERY DISSECTION - TEN YEARS EXPERIENCE OF A TERTIARY CENTER-
- PO 108 THE MISSING MYOCARDIAL INFARCTIONS IN THE COVID-19 PANDEMIC: A REPORT OF A TERTIARY CENTER
- PO 122 IMPACT OF P2Y12 INHIBITORS PRETREATMENT ON DELAY TO CORONARY SURGERY IN A REAL-WORLD POPULATION WITH NSTEMI-ACS
- PO 124 A SINGLE CENTER STUDY OF PATIENTS WHO SUFFERED CARDIAC ARREST WITH A PRESUMED DIAGNOSIS OF ACUTE CORONARY SYNDROME
- PO 145 EARLY VERSUS LATE DEVELOPMENT OF ACUTE KIDNEY INJURY AND ITS PROGNOSTIC RELEVANCE IN ACS PATIENTS
- PO 146 DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME - HIGHER RISK AND LESS WARNING SIGNS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.7 ACUTE CORONARY SYNDROMES - OTHER**

- PO 78 IMPACT OF COVID 19 PANDEMIC IN ACUTE CORONARY SYNDROME ADMISSIONS AND MANAGEMENT

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.3 ACUTE CARDIAC CARE - CCU, INTENSIVE, AND CRITICAL
CARDIOVASCULAR CARE**

- PO 117 VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT FOR ACUTE FULMINANT MYOCARDITIS - A SINGLE-CENTER EXPERIENCE

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.4 ACUTE CARDIAC CARE - CARDIOGENIC SHOCK**

- PO 92 EVOLUTION TRENDS IN THE MANAGEMENT AND PROGNOSIS OF CARDIOGENIC SHOCK IN PORTUGAL
- PO 105 CARDIOGENIC SHOCK IN PATIENTS SEVERE LEFT VENTRICULAR DYSFUNCTION OWING TO ACUTE MYOCARDIAL INFARCTION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.6 ACUTE CARDIAC CARE - OTHER**

- PO 135 CORONAVIRUS DISEASE 2019 (COVID-19) IN THE HEART TRANSPLANT POPULATION: A SINGLE-CENTER EXPERIENCE
- PO 76 IMPELLA FOR CARDIOGENIC SHOCK AND HIGH-RISK PERCUTANEOUS CORONARY INTERVENTION: A SINGLE-CENTER EXPERIENCE

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.1 VALVULAR HEART DISEASE - PATHOPHYSIOLOGY
AND MECHANISMS**

- PO 32 LEFT VENTRICULAR MYOCARDIAL WORK IN PATIENTS WITH HIGH GRADIENT SEVERE SYMPTOMATIC AORTIC STENOSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.2 VALVULAR HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS,
OUTCOME**

- PO 149 ASYMPTOMATIC SEVERE AORTIC STENOSIS: WHAT IS THE CURRENT ROLE OF EXERCISE STRESS TEST AND NT-PROBNP IN PATIENT RISK STRATIFICATION
- PO 156 STAGING CARDIAC DAMAGE IN AORTIC VALVE DISEASE: ONE SIZE FITS ALL?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.3 VALVULAR HEART DISEASE - DIAGNOSTIC METHODS**

PO 180 PREVALENCE AND DETERMINANTS OF RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH SEVERE SYMPTOMATIC HIGH GRADIENT AORTIC STENOSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.4 VALVULAR HEART DISEASE - TREATMENT**

PO 159 TAVI VIA ALTERNATIVE ACCESS ROUTES: PATIENT SELECTION AND 10-YEAR CENTER EXPERIENCE

PO 178 AORTIC VALVE REPLACEMENT IN SEVERE AORTIC STENOSIS: A ROBUSTE IMPACT IN CARDIAC REVERSE REMODELLING

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
16. INFECTIVE ENDOCARDITIS -> 16.2 INFECTIVE ENDOCARDITIS - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

PO 154 THE MAIN PREDICTORS OF IN-HOSPITAL MORTALITY IN PATIENTS WITH INFECTIVE ENDOCARDITIS: A RETROSPECTIVE SINGLE-CENTER STUDY

PO 162 THE IMPACT OF ADMISSION AT A HOSPITAL WITH CARDIOTHORACIC SURGICAL UNIT ONSITE IN THE SURGICAL MANAGEMENT OF PATIENTS HOSPITALIZED WITH INFECTIVE ENDOCARDITIS

PO 164 CLINICAL FEATURES AND OUTCOMES IN PATIENTS WITH ACTIVE INFECTIVE ENDOCARDITIS SUBMITTED TO VALVE SURGERY

PO 167 STAPHYLOCOCCUS AUREUS INFECTIVE ENDOCARDITIS: PREDICTORS AND OUTCOME.

PO 171 NEUROLOGICAL COMPLICATIONS IN INFECTIVE ENDOCARDITIS: RISK FACTORS AND OUTCOME.

PO 28 PROGNOSTIC ROLE OF NEUTROPHIL-LYMPHOCYTE RATIO IN INFECTIVE ENDOCARDITIS: A SIMPLE PREDICTOR FOR A COMPLEX DISEASE?

PO 29 EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS IN PORTUGAL, A POPULATIONAL STUDY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
16. INFECTIVE ENDOCARDITIS -> 16.4 INFECTIVE ENDOCARDITIS - TREATMENT**

PO 163 TYPE OF VALVULAR SURGICAL PROCEDURE IN ACTIVE INFECTIVE ENDOCARDITIS IN PORTUGAL

PO 173 LONG-TERM RESULTS OF MITRAL VALVE REPAIR IN ACTIVE VERSUS CURED ENDOCARDITIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.2 MYOCARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

PO 153 LEFT VENTRICULAR NON-COMPACTION AND ECOSCOREE: PROGNOSTIC VALUE OF A NEW ECHOGRAPHIC RISK SCORE

PO 166 PREVALENCE AND CLINICAL IMPACT OF LATENT OBSTRUCTION IN HYPERTROPHIC CARDIOMYOPATHY

PO 36 IATROGENIC TRANSTHYRETIN CARDIAC AMYLOIDOSIS AFTER SEQUENTIAL LIVER TRANSPLANTATION

PO 37 [18F]FDG-PET IN CARDIAC SARCOIDOSIS: A SINGLE-CENTRE STUDY IN A SOUTHERN EUROPEAN POPULATION

PO 39 ORTHOSTATIC HYPOTENSION IN MUTATED ATTR VAL30MET AMYLOIDOSIS: PREDICTORS AND ASSOCIATED CLINICAL FEATURES

PO 107 CORONARY MICROVASCULAR DYSFUNCTION, MYOCARDIAL FIBROSIS AND IMPAIRED MYOCARDIAL DEFORMATION ARE ASSOCIATED WITH SUPRAVENTRICULAR AND VENTRICULAR ARRHYTHMIC EVENTS IN HYPERTROPHIC CARDIOMYOPATHY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.3 MYOCARDIAL DISEASE - DIAGNOSTIC METHODS**

PO 158 IS DIASTOLIC DYSFUNCTION A GOOD SURROGATE OF FUNCTIONAL CAPACITY IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY?

- PO 181 PATTERNS OF LATE GADOLINIUM ENHANCEMENT IN ACUTE MYOCARDITIS - DOES IT MAKE THE DIFFERENCE?
- PO 34 HOW TO DISTINGUISH BETWEEN HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR HYPERTROPHY SECONDARY TO FABRY DISEASE?
- PO 35 TWIST, LEFT VENTRICULAR LONGITUDINAL AND CIRCUMFERENTIAL STRAIN ARE EARLY MARKERS OF CARDIAC INVOLVEMENT IN FABRY DISEASE
- PO 38 WHICH ECG FEATURES CAN HELP US DIAGNOSE AMYLOIDOSIS IN PATIENTS WITH RESTRICTIVE AND HYPERTROPHIC HEARTS?
- PO 106 MYOCARDITIS DIAGNOSIS BY CMR: WHAT CAN CONFUSE INITIAL DIAGNOSIS?
- PO 108 CORONARY MICROVASCULAR DYSFUNCTION IS ASSOCIATED WITH TISSUE CHANGES AND MYOCARDIAL DEFORMATION IMPAIRMENT IN HYPERTROPHIC CARDIOMYOPATHY - A MAGNETIC RESONANCE IMAGING STUDY
- PO 109 INDEX OF MICROCIRCULATORY RESISTANCE IN THE ASSESSMENT OF CORONARY MICROVASCULAR DYSFUNCTION IN HYPERTROPHIC CARDIOMYOPATHY
- PO 110 THREE-DIMENSIONAL MYOCARDIAL DEFORMATION PARAMETERS ARE ASSOCIATED WITH FUNCTIONAL CAPACITY ASSESSED BY CARDIOPULMONARY EXERCISE TESTING IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 17. MYOCARDIAL DISEASE -> 17.6 MYOCARDIAL DISEASE - CLINICAL

- PO 161 CASES REPORT OF MYOCARDITIS IN A PORTUGUESE TERTIARY HOSPITAL

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.2 CONGENITAL HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 169 CONGENITAL HEART DISEASE: A RETROSPECTIVE ANALYSIS FROM A TERTIARY REFERRAL CENTRE
- PO 91 NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN ADULT CONGENITAL HEART DISEASE: A SINGLE CENTER STUDY
- PO 92 TRENDS IN MORTALITY OF ADULT CONGENITAL HEART DISEASE PATIENTS IN THE LAST FOUR DECADES
- PO 93 CAUSES OF DEATH IN ADULT CONGENITAL HEART DISEASE

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.3 CONGENITAL HEART DISEASE - DIAGNOSTIC METHODS

- PO 182 AORTIC MORPHOLOGY AND DISTENSIBILITY INFLUENCE CLINICAL OUTCOMES AFTER AORTIC COARCTATION TREATMENT

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.4 CONGENITAL HEART DISEASE - TREATMENT

- PO 90 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN ADULT CONGENITAL HEART DISEASE: LONG-TERM FOLLOW-UP OF THERAPIES, COMPLICATIONS AND CLINICAL EVENTS
- PO 94 ARRHYTHMIA ABLATION IN CONGENITAL HEART DISEASE PATIENTS - A SINGLE CENTRE RETROSPECTIVE STUDY

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.7 PEDIATRIC CARDIOLOGY

- PO 183 IMPACT OF PRENATAL DIAGNOSIS OF COARCTATION ON SHORT- AND LONG-TERM CARDIOVASCULAR OUTCOME
- PO 95 DETERMINANTS OF ADVERSE RESPONSE TO EXERCISE IN TREATED AORTIC COARCTATION PATIENTS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE

-> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->

21.2 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 150 RIGHT ATRIAL STRAIN BY SPECKLE-TRACKING ECHOCARDIOGRAPHY AS A PROGNOSTIC PREDICTOR IN A PULMONARY HYPERTENSION COHORT
- PO 151 PROGNOSTIC ACCURACY OF 4 ACUTE PULMONARY EMBOLISM MORTALITY RISK SCORES: EARLY AND LONG TERM PERFORMANCE
- PO 152 “SO I HAVE PULMONARY HYPERTENSION AFTER ALL?”: CHARACTERIZATION AND OUTCOMES OF PATIENTS WITH THE NEW HAEMODYNAMIC DEFINITION OF PULMONARY HYPERTENSION
- PO 155 REAL-WORLD, VERY LONG-TERM FOLLOW UP SURVIVAL OF INCIDENT PATIENTS WITH PULMONARY HYPERTENSION
- PO 157 CAUSES OF DEATH IN PULMONARY ARTERIAL HYPERTENSION PATIENTS: IS THERE SOMETHING ELSE BESIDES THE RIGHT VENTRICLE?
- PO 165 THE RELATIVE PULMONARY TO SYSTEMIC PRESSURE RATIO AS A MEASURE OF PROGNOSTIC VALUE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION - THE NEVER-ENDING QUEST TO IMPROVE RISK STRATIFICATION.
- PO 168 RISK FACTORS FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION - A REAL LIFE EXPERIENCE FROM A PORTUGUESE TERTIARY CENTER
- PO 170 LUNG INVOLVEMENT IN PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS
- PO 172 A NEW RATIO WITH PAO₂/FIO₂ AND PULMONARY ARTERIAL SYSTOLIC PRESSURE IN THE PROGNOSIS OF INTERMEDIATE HIGH RISK PULMONARY EMBOLISM
- PO 177 STAYING TOO STILL: PULMONARY EMBOLISM DURING COVID-19 PANDEMIC
- PO 96 IMPROVING RISK STRATIFICATION OF PULMONARY HYPERTENSION PATIENTS
- PO 97 COMPARISON OF RISK SCORES CALCULATORS IN PATIENTS NEWLY DIAGNOSED WITH PULMONARY ARTERIAL HYPERTENSION
- PO 98 REPERFUSION IN HIGH-RISK ACUTE PULMONARY EMBOLISM: CAN THE PESI SCORE PREDICT OUTCOMES?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.3 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - DIAGNOSTIC METHODS

- PO 176 RIGHT VENTRICULAR OUTFLOW TRACT HYPERTROPHY ASSESSMENT AS A DIAGNOSTIC STRATIFICATION TOOL IN PATIENTS WITH PULMONARY HYPERTENSION
- PO 99 A COMPARATIVE ANALYSIS OF THE DIAGNOSTIC PERFORMANCES OF FOUR CLINICAL PROBABILITY MODELS TO RULE OUT PULMONARY EMBOLISM

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE

-> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->

21.4 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - TREATMENT

- PO 174 CT SCAN FINDINGS PREDICT DECREASE IN PULMONARY VASCULAR RESISTANCE AFTER PULMONARY ENDARTERECTOMY
- PO 100 COMPLICATIONS OF BALLOON PULMONARY ANGIOPLASTY FOR CHRONIC THROMBOEMBOLIC PULMONARY DISEASE ACCORDING THE CLASSIFICATION PROPOSED BY THE 6TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION
- PO 101 COMPARISON OF 2-YEARS FOLLOW-UP OF OPTIMAL MEDICAL THERAPY VERSUS BALLOON PULMONARY ANGIOPLASTY FOR INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: IS IT NOW TIME TO WITHDRAWAL OF ISOLATED MEDICAL THERAPY?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE

-> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->

21.6 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - CLINICAL

- PO 175 DIFFERENT D-DIMER ALGORITHMS TO RULE OUT PULMONARY EMBOLISM IN PATIENTS WITH CANCER: A COMPARATIVE STUDY
- PO 179 PROGNOSTIC VALUE OF CARDIAC BIOMARKERS IN ACUTE PULMONARY EMBOLISM: CAN IT ADD SOMETHING?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE
-> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->
21.7 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - OTHER**

PO 160 INFEÇÃO COVID-19 EM DOENTES COM HIPERTENSÃO ARTERIAL PULMONAR - IMPACTO IMEDIATO E *FOLLOW-UP* A CURTO PRAZO

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE ->
22.1 AORTIC DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

PO 188 AORTIC STENOSIS: MUCH MORE THAN AN ISOLATED HEART DISEASE

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE ->
22.4 AORTIC DISEASE - TREATMENT**

PO 185 AORTIC VALVE INTERVENTION FOR AORTIC STENOSIS AND CARDIAC AMYLOIDOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

PO 187 CARDIOVASCULAR RISK AND CORONARY ARTERY DISEASE BURDEN IN TAVI PATIENTS

PO 189 AORTIC ATHEROSCLEROTIC PLAQUES: THE ROLE OF ANTICOAGULATION

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 24. STROKE -> 24.3 STROKE -
DIAGNOSTIC METHODS**

PO 184 CLINICAL IMPACT OF TRANSOESOPHAGEAL ECHOCARDIOGRAPHY IN ACUTE BRAIN ISCHAEMIA: WHO SHOULD WE SELECT?

**G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 24. STROKE -> 24.5 STROKE -
PREVENTION**

PO 186 COLCHICINE FOR CARDIOVASCULAR PREVENTION IN HIGH-RISK CARDIOVASCULAR PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL
CARDIOLOGY -> 25.1 INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT**

PO 199 DECISION FAILURE IN AMBIGUOUS LESIONS ASSESSED BY CORONARY PHYSIOLOGY EVALUATION

PO 149 PHYSIOLOGIC OR ANGIOGRAPHY GUIDED CORONARY ARTERY BYPASS GRAFTING: A META-ANALYSIS

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL
CARDIOLOGY -> 25.2 CORONARY INTERVENTION**

PO 191 PERCUTANEOUS CORONARY INTERVENTION FOR TRUE BIFURCATION LESIONS: A SINGLE-CENTER EXPERIENCE

PO 193 DISTAL LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION: DOES THE CLINICAL SCENARIO CHANGE THE OUTCOME?

PO 194 BIFURCATION LESIONS AND STENT DIAMETER: IS IT THE BIGGER THE BEST?

PO 197 FEASIBILITY OF CORONARY ANGIOGRAPHY AFTER TAVR

PO 198 PROGNOSTIC IMPACT OF THE PRESENCE AND MANAGEMENT OF CORONARY ARTERY DISEASE IN PATIENTS UNDERGOING TAVI

PO 201 SINGLE STENTING VERSUS DOUBLE STENTING TECHNIQUE IN TRUE BIFURCATION CORONARY LESIONS

PO 202 WHAT IS THE CLINICAL BENEFIT OF CORONARY CHRONIC TOTAL OCCLUSIONS TREATMENT BY PERCUTANEOUS CORONARY INTERVENTION? 2-YEAR EXPERIENCE IN ANGIOGRAPHY LABORATORY.

- PO 203 THE IMPACT OF CORONARY CHRONIC TOTAL OCCLUSION ANGIOPLASTIES ON LEFT VENTRICULAR FUNCTION: 2-YEAR EXPERIENCE IN ANGIOGRAPHY LABORATORY.
- PO 204 WHAT IS THE CLINICAL BENEFIT OF LEFT MAIN CORONARY ARTERY TREATMENT BY PERCUTANEOUS CORONARY INTERVENTION? 2-YEAR EXPERIENCE IN ANGIOGRAPHY LABORATORY.
- PO 205 THE IMPACT OF LEFT MAIN CORONARY ARTERY ANGIOPLASTY ON LEFT VENTRICULAR FUNCTION: 2-YEAR EXPERIENCE IN ANGIOGRAPHY LABORATORY.
- PO 210 IN-HOSPITAL MORTALITY AFTER STEMI IN PORTUGAL: DO PATIENT LOCATION AFFECT OUTCOME?
- PO 211 CORONARY ARTERY PERFORATIONS: 10-YEAR EXPERIENCE OF A LARGE VOLUME CENTRE
- PO 212 PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN DISEASE IN ACUTE CORONARY SYNDROMES: IN-HOSPITAL AND MID-TERM (THREE YEARS) FOLLOW-UP
- PO 213 CLINICAL OUTCOMES IN LEFT MAIN PERCUTANEOUS INTERVENTION: CAN WE DO BETTER?
- PO 215 PERCUTANEOUS CORONARY ANGIOPLASTY OF LEFT MAIN CORONARY ARTERY: DO WE EXCEL?
- PO 216 SAME-DAY DISCHARGE AFTER ELECTIVE UNCOMPLICATED PERCUTANEOUS CORONARY INTERVENTIONS: SAFETY AND FEASIBILITY
- PO 129 LOW RATE OF INVASIVE CORONARY ANGIOGRAPHY FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION: REAL-WORLD PROSPECTIVE COHORT FINDINGS

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.3 NON-CORONARY CARDIAC INTERVENTION

- PO 190 THE IMPACT OF ECHO-GUIDED VERSUS FLUOROSCOPIC FEMORAL ACCESS PUNCTURE ON TRANSCATHETER AORTIC VALVE IMPLANTATION-RELATED VASCULAR COMPLICATIONS
- PO 195 URGENT VERSUS NON-URGENT TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES
- PO 196 GENDER DIFFERENCES AND MORTALITY TRENDS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A 10-YEAR ANALYSIS FROM A SINGLE TERTIARY CENTRE
- PO 206 TRANSCATHETER AORTIC VALVE IMPLANTATION IN VERY OLD PATIENTS: A SINGLE-CENTRE EXPERIENCE
- PO 207 TRANSESOPHAGEAL ECHOCARDIOGRAPHY VERSUS INTRACARDIAC ECHOCARDIOGRAPHY-GUIDED LEFT ATRIAL APPENDAGE OCCLUSION: A COMPARATIVE ANALYSIS
- PO 208 C-REACTIVE PROTEIN AS A PREDICTOR OF POST-TRANSCATHETER AORTIC VALVE IMPLANTATION CONDUCTION DISTURBANCES
- PO 214 IMPACT OF TRANSCATHETER MITRAL VALVE REPAIR ON ECHOCARDIOGRAPHIC PARAMETERS OF THE RIGHT VENTRICLE - A CLOSER LOOK TO THE FORGOTTEN HALF OF THE HEART
 - PO 86 INTRACARDIAC ECHOCARDIOGRAPHY-GUIDED LEFT ATRIAL APPENDAGE OCCLUSION: DESCRIPTIVE ANALYSIS
 - PO 88 ONE-YEAR FOLLOW-UP OF CONTINUOUS ASPIRATION MECHANICAL THROMBECTOMY FOR THE MANAGEMENT OF INTERMEDIATE-HIGH AND HIGH-RISK PULMONARY EMBOLISM: WHAT IS THE LINE BETWEEN UTILITY AND FUTILITY?
- PO 125 PERIPROCEDURAL AND SHORT-TERM STROKE AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION - WHAT ARE THE OUTCOMES AND HOW CAN WE PREDICT IT?
- PO 127 TRANSCAVAL TRANSCATHETER AORTIC VALVE IMPLANTATION: AN ALTERNATIVE
- PO 128 THE TIMING AND MECHANISM OF HIGH-GRADE AV BLOCK POST-TAVI: KNOWING YOUR ENEMY
- PO 142 HIGH-RISK ACUTE PULMONARY EMBOLISM IN A PORTUGUESE CENTRE: ARE WE DOING ENOUGH?

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.4 INTERVENTIONAL CARDIOLOGY - OTHER

- PO 209 IMPACT OF THE COVID-19 PANDEMIC IN THE INTERVENTIONAL CARDIOLOGY: RESULTS OF A TERTIARY CENTRE
 - PO 85 HYBRID THERAPEUTIC APPROACH WITH SPECIFIC DRUG THERAPY AND BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: EFFECTS ON PULMONARY ARTERIAL COMPLIANCE.
 - PO 89 CONTRAST-INDUCED NEPHROPATHY AFTER STAGED BALLOON PULMONARY ANGIOPLASTY: LOWER RISK COMPARED WITH PERCUTANEOUS CORONARY INTERVENTION
- PO 126 LONG TERM DURABILITY OF TRANSCATHETER AORTIC VALVE REPLACEMENT: OUTCOMES FROM A CONTEMPORARY COHORT FROM A TERTIARY REFERENCE CENTER AT 5-YEARS AND BEYOND

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.1 CARDIOVASCULAR SURGERY - CORONARY ARTERIES

- PO 200 CORONARY ARTERY BYPASS GRAFTING SURGERY IN PATIENTS ON PRE-OPERATIVE RENAL REPLACEMENT THERAPY: SAFETY AND LONG-TERM SURVIVAL
- PO 147 MULTIPLE VERSUS SINGLE ARTERIAL GRAFTING IN THE ELDERLY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PROPENSITY SCORE STUDIES
- PO 148 OFF-PUMP VERSUS ON-PUMP CORONARY ARTERY BYPASS GRAFTING IN MULTI-VESSEL CORONARY ARTERY DISEASE: A PROPENSITY SCORE-MATCHED ANALYSIS OF SAFETY AND LONG-TERM RESULTS
- PO 150 A META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES COMPARING OFF-PUMP VERSUS ON-PUMP CABG IN THE ELDERLY

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.8 CARDIOVASCULAR SURGERY - TRANSPLANTATION

- PO 192 RIGHT VENTRICULAR FUNCTION PARAMETERS AS THE BEST ACUTE CELLULAR REJECTION PREDICTORS

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.11 CARDIOVASCULAR SURGERY - OTHER

- PO 151 HEART SURGERY WAITING LIST MANAGEMENT IN AN ULTRA-PERIPHERAL REGION - EXPERIENCE OF A CENTER IN PORTUGAL
- PO 152 IMPACTO AMBIENTAL DA SUBSTITUIÇÃO CIRÚRGICA DA VÁLVULA AÓRTICA

I. HYPERTENSION -> 27. HYPERTENSION -> 27.1 HYPERTENSION - PATHOPHYSIOLOGY AND MECHANISMS

- PO 217 GENETIC POLYMORPHISMS ASSOCIATED WITH THE ONSET OF ESSENTIAL HYPERTENSION IN THE DIABETIC POPULATION
- PO 218 INTERACTION BETWEEN GENETIC AND NON-GENETIC FACTORS IN THE APPEARANCE OF KIDNEY FAILURE/MICROALBUMINURIA IN HYPERTENSIVE INDIVIDUALS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.1 RISK FACTORS AND PREVENTION - EPIDEMIOLOGY

- PO 49 EPICARDIAL ADIPOSE TISSUE (EAT) VOLUME IS RELATED TO SUBCLINICAL ATHEROSCLEROSIS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN ASYMPTOMATIC SUBJECTS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.2 RISK FACTORS AND PREVENTION - CARDIOVASCULAR RISK ASSESSMENT

- PO 221 ROLE OF TRIGLYCERIDES AND HDL CHOLESTEROL IN RESIDUAL RISK IN CORONARY ARTERY DISEASE PATIENTS WITH LOW LDL CHOLESTEROL
- PO 230 EPICARDIAL ADIPOSE TISSUE VOLUME IMPROVES CARDIOVASCULAR RISK RECLASSIFICATION: THE FRAMINGHAM RISK SCORE EXAMPLE
- PO 234 CORONARY ARTERY CALCIFICATION SCORE CAN PREDICT CARDIOVASCULAR DISEASE IN ASYMPTOMATIC PATIENTS WITH METABOLIC SYNDROME
- PO 236 PULSE WAVE VELOCITY CAN DETECT HIGH CARDIOVASCULAR RISK IN ASYMPTOMATIC PATIENTS WITH METABOLIC SYNDROME
- PO 47 MORTALITY OF YOUNG PATIENTS WITH SEVERE CORONARY DISEASE AND NO IDENTIFIABLE CARDIOVASCULAR RISK FACTORS
- PO 48 IS THERE A DIFFERENT IMPACT OF TRADITIONAL RISK FACTORS ON CORONARY CALCIUM SCORE, IN AN ASYMPTOMATIC POPULATION?

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.3 SECONDARY PREVENTION

- PO 219 BUDGET IMPACT ANALYSIS AND PUBLIC HEALTH BENEFIT OF THE CNIC POLYPILL STRATEGY FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASE IN PORTUGAL
- PO 227 ANTICIPATING RECURRENT ISCHEMIC EVENTS AFTER AN ACUTE CORONARY SYNDROME: VALIDATION AND APPLICATION OF THE SMART-REACH SCORE

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.7 DIABETES AND THE HEART

- PO 224 ASSESSING THE CLINICAL UTILITY OF A GENETIC RISK SCORE CONSTRUCTED USING 10 SUSCEPTIBILITY SNPS ASSOCIATED WITH TYPE 2 DIABETES IN A SOUTHERN EUROPEAN POPULATION

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.12 PHYSICAL INACTIVITY AND EXERCISE

- PO 226 THE IMPACT OF COVID-19 ERA IN CARDIAC REHABILITATION PROGRAMS: WERE CARDIOVASCULAR PATIENTS ABLE TO REMAIN PHYSICALLY ACTIVE?

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.14 RISK FACTORS AND PREVENTION - OTHER

- PO 223 ESSENTIAL HYPERTENSION AND ATP2B1 GENE ARE ASSOCIATED WITH EARLY ARTERIAL STIFFNESS
- PO 45 HOW COST-EFFECTIVE IS THE CNIC POLYPILL FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASE IN PORTUGAL? AN ASSESSMENT OF ITS HEALTH- ECONOMIC VALUE
- PO 50 CARDIOVASCULAR RISK FACTOR CONTROL: IS IT POSSIBLE WITH A HOME-BASED CARDIAC REHABILITATION PROGRAM?

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.1 EXERCISE TESTING

- PO 220 END-TIDAL CARBON DIOXIDE PARTIAL PRESSURE - A NEW PROGNOSTIC MARKER AFTER ACUTE MYOCARDIAL INFARCTION?

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.2 CARDIOVASCULAR REHABILITATION

- PO 222 IDENTIFICATION OF DIASTOLIC DYSFUNCTION ON CARDIOPULMONARY EXERCISE TESTING AND ITS PROGNOSTIC VALUE
- PO 225 THE IMPACT OF COVID-19 ERA IN PHASE III CARDIAC REHABILITATION PROGRAMS: HOW WAS BODY COMPOSITION AFFECTED IN TRAINED CARDIOVASCULAR PATIENTS?
- PO 228 THE IMPACT OF CHRONOTROPIC INCOMPETENCE MARKERS IN A POPULATION UNDERGOING CARDIAC REHABILITATION
- PO 229 PROGNOSTIC POWER OF PEAK OXYGEN PULSE IN A POPULATION UNDERGOING CARDIAC REHABILITATION
- PO 231 CARDIOPULMONARY EXERCISE TESTING IN ASYMPTOMATIC AORTIC STENOSIS
- PO 232 HOME-BASED CARDIAC REHABILITATION - THE PATIENTS WANT BUT DO THEY ADHERE?
- PO 233 HOME-BASED CARDIAC REHABILITATION IN COVID ERA: IS IT A SAFE OPTION?
- PO 235 LEFT VENTRICULAR REMODELING: IS THERE A REAL IMPACT OF CARDIAC REHABILITATION?
- PO 238 IMPACT OF A COMPREHENSIVE PHASE II CARDIAC REHABILITATION PROGRAM ON LEFT VENTRICULAR FUNCTION, CARDIORESPIRATORY FITNESS AND LIPID PROFILE IN CARDIOVASCULAR PATIENTS
- PO 46 HOW TO COUNTERACT PHYSICAL INACTIVITY DURING COVID-19 PANDEMIC THROUGH A DIGITAL HOME-BASED MULTIDISCIPLINARY CARDIAC REHABILITATION PROGRAM?
- PO 64 CARDIOPULMONARY EXERCISE TEST AND SUDDEN CARDIAC DEATH RISK IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS

- PO 66 PEAK CIRCULATORY POWER IS A STRONG PROGNOSTIC FACTOR IN PATIENTS UNDERGOING CARDIAC REHABILITATION
PO 68 HOME-BASED CARDIAC REHABILITATION - THE REAL BARRIERS OF PROGRAMS AT DISTANCE

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.4 REHABILITATION AND SPORTS CARDIOLOGY - OTHER

- PO 237 HOME-BASED CARDIAC REHABILITATION IN COVID ERA: IS IT A SAFE OPTION?

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.3 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS: PEDIATRIC CARDIOLOGY

- PO 111 HYPERTROPHIC CARDIOMYOPATHY IN A PEDIATRIC POPULATION

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.5 CARDIOVASCULAR DISEASE IN THE ELDERLY

- PO 136 THE 90S ARE THE NEW 70S: APPROACH TO NONAGENARIAN PATIENTS WITH MYOCARDIAL INFARCTION: DATA FROM THE REAL WORLD REGISTRY ON ACUTE CORONARY SYNDROMES

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.6 CARDIO-ONCOLOGY

- PO 239 PREVENTIVE STRATEGIES FOR ANTHRACYCLINES AND TRASTUZUMAB INDUCED CARDIOTOXICITY: A SYSTEMATIC REVIEW AND META-ANALYSIS
PO 240 THE PREDICTIVE ROLE OF SPECKLE-TRACKING AND LEFT VENTRICULAR EJECTION FRACTION ESTIMATION USING 2D AND 3D ECHOCARDIOGRAPHY FOR THE DETECTION OF SUBCLINICAL AND CLINICAL CARDIAC DYSFUNCTION DUE TO ANTHRACYCLINES: A SYSTEMATIC REVIEW
PO 242 RIGHT VENTRICULAR FUNCTION AFTER BREAST CANCER CHEMOTHERAPY
PO 135 MORBIDITY AND MORTALITY IN CARDIO-ONCOLOGY CLINIC PATIENTS - WHO'S THE GUILTY ONE: IS IT THE HEART, THE CANCER OR THE PATIENT?
PO 137 MYOCARDIAL WORK BRINGS A NEW INSIGHT INTO LEFT VENTRICLE REMODELLING IN CARDIOONCOLOGY PATIENTS
PO 138 DEXRAZOXANE ROLE IN THE PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN CHILDREN WITH ACUTE LEUKEMIA: A META-ANALYSIS
PO 140 PREVENTIVE ROLE OF CARDIOPROTECTIVE DRUGS IN HER2 POSITIVE BREAST CANCER

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.14 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS - OTHER

- PO 241 CARDIOVASCULAR DISEASE IN AN INTENSIVE CARE UNIT: PATTERNS OF AN OFTEN FATAL OMEN
PO 243 FIGHTING THE PANDEMIC WITH COLLABORATION AT HEART: REPORT FROM CARDIOLOGISTS IN A COVID-19 DEDICATED PORTUGUESE INTENSIVE CARE UNIT
PO 139 OI&HEART STUDY: CARDIOVASCULAR PROFILE OF PORTUGUESE PATIENTS WITH OSTEOGENESIS IMPERFECTA

L. CARDIOVASCULAR PHARMACOLOGY -> 31. PHARMACOLOGY AND PHARMACOTHERAPY -> 31.1 CARDIOVASCULAR PHARMACOTHERAPY

- PO 244 EFFICACY AND SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND COLCHICINE IN MYOPERICARDITIS
PO 133 DIRECT ORAL ANTICOAGULANTS COMPARED WITH VITAMIN K ANTAGONISTS FOR LEFT VENTRICULAR THROMBI: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.1 ACUTE NURSING CARE

- PO 10 BOAS PRÁTICAS DO ENFERMEIRO NA COLHEITA DE AMOSTRAS PARA HEMOCULTURAS NUMA UNIDADE DE CUIDADOS INTENSIVOS CARDÍACOS DE UM CENTRO HOSPITALAR DA ZONA NORTE DE PORTUGAL: O PAPEL DA FORMAÇÃO E DA INTRODUÇÃO DE UM PROCEDIMENTO PADRÃO NA DIMINUIÇÃO DAS TAXAS DE CONTAMINAÇÃO

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.2 CHRONIC NURSING CARE

- PO 248 A INSUFICIÊNCIA CARDÍACA E A COVID-19: ANÁLISE DO IMPACTO NA QUALIDADE DE VIDA

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.3 CARDIOVASCULAR NURSING - OTHER

- PO 245 QUALIDADE DE VIDA DOS DOENTES INSERIDOS NUM PROGRAMA DE ENFERMAGEM DE REABILITAÇÃO
- PO 246 ESTADO DE SAÚDE DOS DOENTES INSERIDOS NUM PROGRAMA DE ENFERMAGEM DE REABILITAÇÃO
- PO 247 A SEGURANÇA DO DOENTE NA CARDIOLOGIA: O CASO DAS TRANFERÊNCIAS DE INFORMAÇÃO
- PO 6 INDICADORES DE ENFERMAGEM SENSÍVEIS AOS CUIDADOS DE ENFERMAGEM DE REABILITAÇÃO EM CARDIOLOGIA - EXPERIÊNCIA DE UM CENTRO
- PO 7 PREVENÇÃO DA INFEÇÃO DO LOCAL CIRÚRGICO NA IMPLANTAÇÃO DE DISPOSITIVOS CARDÍACOS: CONTRIBUTOS PARA UM CUIDADO DE ENFERMAGEM DE EXCELÊNCIA
- PO 8 MOMENTO DE EXERCÍCIOS DE ALONGAMENTO - SATISFAÇÃO DOS PROFISSIONAIS DE SAÚDE
- PO 11 ADESAO AO REGIME TERAPÊUTICO DOS DOENTES SUBMETIDOS A CIRURGIA CARDÍACA - UM ESTUDO RETROSPECTIVO

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.4 DIGITAL HEALTH

- PO 249 WHAT ARE THEY SAYING ABOUT ACUTE MYOCARDIAL INFARCTION ON YOUTUBE?
- PO 251 BUILDING A NEW PCI CENTRE WITH THE HELP OF PROCESS MINING TOOLS

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.5 E-CARDIOLOGY - OTHER

- PO 250 THE IMPACT OF DIGITAL FLASHCARDS ON CARDIOVASCULAR PHYSIOLOGY ACADEMIC PERFORMANCE IN A MEDICAL COURSE - A CONSISTENT DOSE-DEPENDENT EFFECT BETWEEN THE AMOUNT OF TRAINING AND ACADEMIC SUCCESS

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.3 HEALTH ECONOMICS

- PO 252 UTILITY AND COST OF ROUTINE BLOOD TEST PROFILES IN ACUTE CORONARY SYNDROME: A MULTICENTER SURVEY STUDY
- PO 253 NT-PROBNP INAPPROPRIATE SHORT-TERM REPEAT TESTING IS ASSOCIATED WITH ELEVATED HEALTHCARE COSTS

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.2 BASIC SCIENCE - CARDIAC BIOLOGY AND PHYSIOLOGY

- PO 255 PLASMA KINESIS AND PROGNOSTIC IMPACT OF CRP IN STEMI PATIENTS
- PO 25 HOMEOSTASIS RESCUE: THE EFFECT OF DRUG VERSUS LIFESTYLE APPROACH IN LOW DOSE OF DOXORUBICIN TREATED RATS

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.3 BASIC SCIENCE - CARDIAC DISEASES

- PO 254 CHARACTERIZATION OF PLASMA ACYLCARNITINES IN OBESE PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 26 MULTI-SPECIES TRANSCRIPTOMIC DATA ANALYSIS REVEAL THREE CANDIDATE GENES, RESPONSIBLE FOR THE TRANSITION FROM COMPENSATED LEFT VENTRICLE HYPERTROPHY TO HEART FAILURE
- PO 27 KETOGENIC DIET AS A THERAPEUTIC OPTION ON A RAT MODEL OF HEART FAILURE

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.5 BASIC SCIENCE - VASCULAR DISEASES

- PO 23 METABOLIC REPROGRAMMING IN PULMONARY ARTERIAL HYPERTENSION: IS IT A CANCER-LIKE DISEASE?

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.6 BASIC SCIENCE - OTHER

- PO 24 PHYSICAL EXERCISE OR ATENOLOL: WHAT IS THE BEST STRATEGY TO COUNTERACT THE BEHAVIORAL MODIFICATIONS INDUCED BY LOW DOSES OF DOXORUBICIN?

P. OTHER -> 37. MISCELLANEA

- PO 256 NORMAL VALUES OF THE ELECTROCARDIOGRAM IN ANGOLANS
- PO 257 HEMODYNAMIC AND AUTONOMIC NERVOUS SYSTEM (ANS) OUTPUT CHANGES AFTER BARIATRIC SURGERY.
- PO 258 LONG-TERM EXPERIENCE OF NON-VITAMIN K ORAL ANTICOAGULANTS IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION
- PO 65 ESTIMATING PVO₂ AND PROGNOSIS THROUGH CARDIAC EXERCISE STRESS TEST IN A HEART FAILURE POPULATION
- PO 87 VALIDAÇÃO DO SCORE SPESI NUMA POPULAÇÃO DE UM HOSPITAL PORTUGUÊS
- PO 130 LEFT VENTRICLE REMODELLING AND MECHANICAL IMPROVEMENT AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY
- PO 131 AVALIAÇÃO DA CAPACIDADE DA FUNCIONAL POR TESTE DE MARCHA APÓS INFEÇÃO POR COVID 19
- PO 132 CATH LAB ACTIVITY DURING COVID-19 PANDEMIC: REPORT FROM ONE CENTRE
- PO 134 SÍNDROME MULTISSISTÉMICO PEDIÁTRICO TEMPORALMENTE ASSOCIADO A INFEÇÃO SARS-COV2: ESTUDO DE 6 CASOS